© Reuters. FILE PHOTO: Take a look at tubes are seen in entrance of a displayed AstraZeneca brand on this illustration taken, Might 21, 2021. REUTERS/Dado Ruvic/Illustration/File Picture
(Reuters) – AstraZeneca (NASDAQ:) stated on Tuesday it has agreed to purchase clinical-stage biopharmaceutical firm Fusion Prescribed drugs Inc for about $2 billion in money.
The drugmaker can pay $21 per Fusion share plus a non-transferable contingent worth proper of $3 per share.